milestones news from FierceBiotech
News
Theravance wins $10M milestone on Phase II data
Mid-stage data from an experimental COPD therapy under development by GlaxoSmithKline researchers came in positive, and that will be worth a $10 million milestone payment for Theravance. Theravance Read more...
Lilly pays $35M to land TransPharma pact
Eli Lilly is forking over a $35 million upfront payment to nail down the worldwide licensing rights to TransPharma Medical's ViaDerm-hPTH osteoporosis product and a non-exclusive license to its Read more...
Ipsen inks a string of deals in expansion effort
France's Ipsen is buying out Tercica in a $404 million deal, one of three new pacts designed to Read more...
Exelixis gets $150M credit line
Exelixis has struck a $150 million financing deal with Deerfield Management. At Exelixis discretion, the developer can draw down the money as needed over the next 18 months in $15 million Read more...
SPOTLIGHT: Anesiva inks $114M licensing deal
Transcription Factor Therapeutics has licensed the worldwide rights to Anesiva's NF-kB Decoy program, which includes the clinical drug candidate Avrina. NF-kB Transcription Factor Decoy inhibits Read more...
SPOTLIGHT: Antisoma gets $25M milestone from Novartis
Antisoma has received a $25 million milestone payment from Novartis, triggered by the recent initiation of a phase III trial of ASA404 in non-small cell lung cancer. Read more...
Lexicon cuts staff, focuses on R&D
Lexicon is reorganizing and cutting staff as it pursues its aggressive strategy to build its pipeline. The cuts will allow Lexicon to devote its resources to its strategic, business, and clinical Read more...
Migenix cuts costs to stretch cash
Canada's Migenix is cutting its staff in an effort to preserve cash. The company, which is developing the anti-infective drug Omigard, cut six workers, reduced its CEO's salary and downsized its Read more...
JapanBridge pays $26M for ProStrakan patch
JapanBridge is paying $26 million in upfront and milestone payments for the rights to develop and commercialize Sancuso, a transdermal patch for the prevention of chemotherapy-induced nausea and Read more...
Myriad Genetics pencils in $350M deal for Flurizan
Myriad Genetics has landed a key partnership for its late-stage Alzheimer's therapy. H. Lundbeck has agreed to pay $100 million in an upfront fee along with $250 million in milestones for the Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets